Alignment Healthcare's 86.3% MBR Rides a High-Acuity SNP Bet

Alignment Healthcare's adjusted medical benefit ratio fell to 86.3% in the second quarter of 2026, the lowest since its 2021 IPO, even as half of the 31% membership growth it added came from chronic special needs plan (C-SNP), dual-eligible special needs plan (D-SNP), or full dual-eligible members, a cohort that raises near-term claims cost ahead of the risk-adjustment revenue calibrated to match it (Alignment Healthcare, July 30, 2026).

86.3%

Alignment's adjusted MBR in Q2 2026, down 40 basis points year over year and the lowest since its 2021 IPO.

50%

Share of 2026 new members entering as C-SNP, D-SNP, or full dual-eligible, a higher-acuity mix than the base book.

294,100

Total health plan membership at quarter end, up 31% year over year.

A Named-Actor Quarter: What Alignment Actually Reported

Alignment CEO John Kao and CFO Thomas Freeman laid out a quarter built on two simultaneous claims: the ratio improved and the mix got harder. Total revenue reached $1.34 billion, up 32% year over year, while net income more than doubled to $36.6 million from the prior-year quarter (Alignment Healthcare Form 8-K, July 30, 2026). Adjusted EBITDA came in at $68.1 million, a 5.1% margin and 60 basis points of year-over-year expansion, while adjusted gross profit reached $183 million against adjusted SG&A held to 8.6% of revenue (The Motley Fool earnings call transcript, July 30, 2026). Cash and liquidity stood at $702 million, and first-half operating cash flow reached $111 million against a funded leverage ratio of 2.2 times trailing-twelve-month EBITDA, a balance sheet capable of absorbing a rougher ratio than the one the company reported.

The company raised full-year 2026 guidance to $5.20 billion to $5.23 billion in revenue and $145 million to $163 million in adjusted EBITDA, both above the ranges it had set entering the year (Alignment Healthcare, July 30, 2026). On the acuity mix specifically, Freeman told analysts: "New member mix year over year, we just have more acuity in the new member mix, which is adding a little bit more to the MBR across the board," directly attributing part of the ratio's composition, not its direction, to the SNP and dual-eligible cohort (Motley Fool earnings call transcript, July 30, 2026). That single sentence is the mechanism this quarter's headline ratio was built on top of, and it is the part a benefit-ratio-only read of the release misses entirely.

Why Acuity Mix Changes the Ratio's Meaning, Not Just Its Level

A medical benefit ratio blends two moving pieces that a single percentage cannot separate: the medical cost a member actually incurs and the risk-adjusted revenue CMS pays to cover that cost. For a stable, seasoned membership base, both sides move together and the ratio behaves as a clean read on care-management efficiency. A cohort of new SNP and dual-eligible members breaks that symmetry in a specific, well-understood direction. These members typically present with more diagnosed chronic conditions, higher near-term utilization, and, for duals, wraparound Medicaid-covered costs that complicate cost attribution, all of which hit the claims side of the ratio in month one. The revenue side lags behind it: CMS Hierarchical Condition Category (HCC) risk scores for a new member are built from diagnosis codes submitted during the plan's own encounters, which means a member enrolled in January is not fully risk-scored, and the plan is not fully paid for that member's true risk, until well into the following payment year.

That lag is the reason Alignment's management describes the SNP and dual push as an intentional, multi-quarter investment rather than a one-quarter cost problem. Freeman's framing on the call, that the mix "is adding a little bit more to the MBR across the board," is consistent with a book where the front half of the risk-adjustment cycle is underway and the back half, the revenue catch-up, has not yet cleared. An MBR that still improved 40 basis points while absorbing that drag is a stronger underlying signal than the same ratio would be on a flat-mix book, because it means the Care Anywhere clinical model and the AVA AI stratification tool, which the company says predicts the roughly 10% of members likely to drive nearly 70% of hospital admissions in the next 30 days, are offsetting a real, quantifiable headwind rather than coasting on an easy comparison.

How This Differs From the Clover Story Already on the Site

Alignment's quarter arrives four weeks after Clover Health reported a 87.6% benefit expense ratio on 49% Medicare Advantage membership growth, and the surface pattern looks identical: a smaller, fast-growing plan improving its ratio while adding members. The mechanism underneath is different. Clover's ratio improvement traced to cohort maturation, members who joined in 2025 producing markedly better economics in their second year than their first, a story about the passage of time inside a relatively standard-acuity book. Alignment's ratio improvement is happening despite, not because of, its 2026 cohort composition; half of that cohort entered at a structurally higher acuity level than the base book, and the ratio held anyway. Clover's growth question is whether the maturation curve keeps working as growth decelerates. Alignment's growth question is whether risk-adjustment revenue and care-management savings catch up to the acuity it deliberately took on, a question about a specific coding and clinical-intervention cycle rather than about time alone.

The dual-eligible and SNP concentration Alignment is leaning into is also not an idiosyncratic choice; it tracks an industry-wide shift. D-SNP enrollment has nearly tripled from 2.2 million to 6.0 million members since 2018, and SNP margins now run roughly double the broader Medicare Advantage average, which is the structural reason multiple carriers are chasing this segment even though it is the hardest one to underwrite in a member's first year on the plan.

The 2027 Setup: 20% Growth Into a Star Ratings Fight Alignment Started Itself

Management guided to roughly 20% enrollment growth for 2027, with new-market entries inside Alignment's existing state footprint and out-of-state expansion targeted for 2028, alongside service-area expansion filings due in February 2027 (Motley Fool earnings call transcript, July 30, 2026). A growth rate at that scale, layered onto a 2026 cohort that is still working through its own risk-adjustment catch-up, compounds the acuity-mix dynamic rather than resolving it: each new enrollment year adds another tranche of under-coded, front-loaded-cost membership before the prior tranche has fully cleared.

Star ratings sit directly inside that 2027 bid math, and Alignment is not a bystander in the current litigation wave. CEO Kao told analysts, "The regulatory and kind of legal footing surrounding stars is a little shaky right now" (Motley Fool earnings call transcript, July 30, 2026), a comment that undersells the company's own position. Alignment sued CMS in January 2026 over what it called significant errors in its star ratings calculation and won a partial victory that raised its Arizona HMO contract from 3.5 to 4 stars. It filed again on July 10, 2026, in the U.S. District Court for the District of Columbia, seeking the same recalculation methodology CMS applied after Clover Insurance Company v. HHS, a case that found 20 measures in CMS's 2026 star ratings calculation unlawful. Alignment's complaint states the company was deprived of $50 million because CMS declined to extend Clover's recalculation to its own contracts. Two other carriers are pursuing the identical argument: Elevance sued CMS on July 1, 2026 over roughly $115 million tied to the same unapplied recalculation, and SCAN Health Plan filed a parallel suit the same month, meaning at least three Medicare Advantage organizations are now litigating the same star ratings methodology question simultaneously.

Quality bonus payments funded through star ratings directly finance the supplemental benefits that make a Medicare Advantage bid competitive, so an unresolved star ratings dispute is not a side issue for 2027 pricing; it is a bid input still in motion at the exact moment Alignment is planning its most aggressive growth year. CMS's broader risk-adjustment posture adds a second layer of 2027 uncertainty: the agency proposed recalibrating its CMS-HCC Version 28 model with more recent fee-for-service data in the 2027 Advance Notice, then declined to finalize that change, citing a desire to give the market more time to adjust to V28's full-weight phase-in, so the coefficients built on 2018 diagnosis and 2019 expenditure data carry forward into 2027 unchanged (Georgetown Center for Children and Families, 2026). CMS did finalize two narrower changes for 2027: diagnoses drawn from unlinked chart-review records and from audio-only encounters no longer count toward risk scores, a change that falls disproportionately on plans, like Alignment's, that lean on SNP and dual-eligible outreach where telephonic and chart-review coding capture a larger share of documented conditions than in a standard-acuity book.

2027 pressure point	Mechanism	Effect on Alignment's bid
Star ratings litigation	Alignment, Elevance, SCAN separately suing CMS over unapplied Clover-style recalculation	$50M quality-bonus claim unresolved heading into the 2027 bid cycle
V28 recalibration deferral	CMS kept 2018/2019 base data rather than updating to current FFS experience	Removes one source of 2027 revenue uncertainty, but leaves the full-weight compression from 2026 in place
Audio-only and chart-review exclusions	Those diagnosis sources no longer count toward HCC risk scores starting 2027	Disproportionately affects SNP/dual outreach coding relative to standard-acuity members

The Coding and Legal-Risk Overhang

The same diagnosis-coding process that determines how quickly risk-adjustment revenue catches up to a high-acuity cohort is also the process under the heaviest federal scrutiny in Medicare Advantage. The Department of Justice announced a $556 million False Claims Act settlement with five Kaiser Permanente affiliates on January 14, 2026, the largest Medicare Advantage risk-adjustment fraud resolution to date, over allegations that Kaiser used "queries" to prompt providers to add diagnoses months after a visit, tied physician compensation to risk-adjustment coding targets, and retained diagnoses lacking clinical support despite internal compliance warnings (Bass, Berry & Sims, January 2026). DOJ said those practices generated roughly $1 billion in unsupported CMS payments tied to nearly 500,000 added diagnoses, a figure that dwarfs the two next-largest prior settlements, Cigna's $172 million in 2023 and Independent Health's $100 million in 2024. The enforcement pattern has not slowed since: a national insurer paid $117.7 million in March 2026 over allegedly inaccurate or unwithdrawn diagnosis codes, and a $56.5 million settlement followed in June 2026 on similar allegations.

Alignment's own regulatory exposure runs through the audit channel rather than a False Claims Act complaint. Its California HMO plan was notified on June 25, 2025 that it had been selected for a CMS Risk Adjustment Data Validation (RADV) audit covering payment year 2019, a routine but consequential process in which CMS samples member charts to confirm the diagnoses a plan submitted are documented and supportable (Alignment Healthcare Form 10-Q, 2026). The audit's stakes changed materially under a 2023 CMS final rule that applies extrapolated audit findings to the full contract rather than only to sampled members, without the fee-for-service adjuster that had previously discounted findings for the error rate baked into CMS's own underlying claims data. Removing that adjuster means a given rate of unsupported diagnoses in a sample now extrapolates to a larger contract-wide recoupment than the identical finding would have produced under the prior methodology, raising the financial consequence of any adverse RADV finding across the industry, Alignment included, independent of whether its coding practices resemble Kaiser's.

None of this implicates Alignment in wrongdoing; RADV selection is a standard CMS process applied across Medicare Advantage plans, and Alignment has disclosed no allegation resembling the Kaiser case's fact pattern. The relevance to this quarter's MBR story is structural rather than accusatory: a plan whose growth strategy depends on capturing risk-adjustment revenue quickly and accurately on a fast-growing SNP and dual-eligible book is, by definition, generating more diagnosis-coding volume in the exact population segment where CMS audit and DOJ enforcement attention is concentrated. An adverse RADV finding on even a modest share of the 2019 sample, extrapolated under the post-2023 methodology, would show up as a retrospective reduction to booked risk-adjustment revenue rather than a claims-cost increase, the opposite side of the MBR equation from where this quarter's acuity-mix pressure showed up, and a reserving actuary modeling Alignment's forward MBR trajectory has to hold both possibilities open simultaneously.

What the Ratio Says About the Next Two Quarters

The mechanical implication of a front-loaded acuity cohort is that the third and fourth quarters of 2026 should show the SNP and dual-eligible members enrolled earlier in the year converting from a cost drag into a more accurately risk-scored, better-managed cohort, provided the AVA stratification tool and Care Anywhere care-management model perform as management described. If that conversion tracks on schedule, the 86.3% MBR is closer to a floor than a peak for 2026, consistent with the raised full-year EBITDA guidance. If the 2027 growth guidance of roughly 20% repeats this year's mix skew, at a larger scale, the company effectively resets the clock on a new front-loaded cohort just as the current one finishes catching up, a treadmill dynamic that a bid actuary has to price explicitly rather than assume away by extrapolating the current quarter's improving trend line indefinitely.

That is the actuarial distinction this quarter's headline ratio obscures. An 86.3% MBR achieved on a stable-mix book and an 86.3% MBR achieved while absorbing a 50% high-acuity new-member share are not the same underlying risk, even at an identical reported number, and the gap between them is exactly the risk-adjustment timing lag and RADV exposure this quarter's release does not fully resolve.